Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Next Up For AstraZeneca: Building Out In Renal Disease

Executive Summary

US President Ruud Dobber talked to Scrip about expanding in renal disease, balancing the fast-growing oncology portfolio against other priority disease areas, and the company's anticipated return to growth. The big challenge going into 2019, he said, is external factors. "I'm not able to change the view of the President," he said.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC124052

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel